Arrayit, Sunnyvale, Calif, offers the market’s first service dedicated exclusively to elucidating orphan human diseases. These rare conditions present in a small percentage of the population, with one case typically occurring for every 1,000 to 200,000 persons. Arrayit deploys its patented, proprietary microarray platform on a genomic scale to rapidly elucidate an orphan disease’s molecular basis. Control and test samples of mRNA are compared to produce a gene expression signature for each condition, and gene expression data are computationally examined to produce a “best-fit” biological pathway. The sensitivity and specificity of the microarray platform enable a deeper examination of the transcriptome than many competing platforms and a more complete understanding of orphan diseases. The company also offers genotyping and proteomic analyses to confirm and extend each analysis. For more information, visit Arrayit.
June 19, 2018
April 12, 2021